Zydus Cadila becomes second Indian pharma with US IND for GK activator in diabetes
This article was originally published in Scrip
Executive Summary
Zydus Cadila, one of India’s leading healthcare companies announced that it has received an IND approval from the US FDA for ZYGK1, an orally administered small molecule glucokinase activator for Type 2 diabetes. The move reinforces Zydus' transition from its heavy dependence on generics to its ambitions as a research-led company. It also makes Zydus the second Indian company exploring the glucokinase activation space, alongside Advinus.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.